Insmed (INSM) Stock: Buy, Sell, or Hold?
$120.75
+1.26 (+1.05%)
▲
5d:
+9.77%
30d:
+24.75%
90d:
-4.42%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Oct 29, 2026
0d
Protect INSM Gains
Updated Nov 11, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (24%)
Quality Score
37/100
Position
EXTENDED
30-Day Fair Range
$94.89 – $111.30
Position: EXTENDED
Forward P/E & Valuation
183.5x
CHEAP
vs 227.6x historical avg
Wall Street Target
$194.18
+60.8% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$102.69 / $120.88
Trend: Sideways
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: INSM shows conflicting indicators. Wait for confirmation before entering.
Get Alerted When INSM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$23.05
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$14.31
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: INSM is currently trading at $120.75, which is considered extended relative to its 30-day fair value range of $94.89 to $111.30. From a valuation perspective, the stock is trading at a discount (Forward PE: 183.5) compared to its historical average (227.6). Remarkably, the market is currently pricing in an annual earnings decline of 6.9% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, INSM is showing sideways momentum. The price is approaching resistance at $120.88. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: INSM scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $194.18 (+60.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, INSM is showing sideways momentum. The price is approaching resistance at $120.88. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: INSM scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $194.18 (+60.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$94.89 -
$111.30
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
23.8%
Trading Range & Key Levels
30-Day Trading Range
$94.89 -
$111.30
Current vs Trading Range
EXTENDED
Support Level
$102.69
Resistance Level
$120.88
Current Trend
Sideways
Technical data as of
Nov 11, 2026
Protect Your Profits
Holding INSM? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- BEARISH: Price extended above range (+8.5% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 60.8% below Wall St target ($194.18)
- WARNING: Composite score 37/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
183.48
Wall Street Target
$194.18
(+60.8%)
Revenue Growth (YoY)
268.4%
Profit Margin
-39.9%
Valuation Discount vs History
-6.9% cheaper
PE vs Historical
183.5 vs 227.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.9%
(market-implied from PE analysis)
1-Year Target
$112.42
(-7%)
2-Year Target
$104.66
(-13%)
3-Year Target
$97.44
(-19%)
3-Yr Target (if PE normalizes)
(PE: 183→228)
$120.87
(+0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 183.5 to 227.6
Stabilization Target:
$149.78
(+24.0%)
PE Expansion Potential:
+24.0%
Share INSM Analysis
Share this live INSM analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (INSM)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 2, 2026
Daily AI digest
AI Retail Discussion Summary:
RBC sees potential upside for $INSM if Brinsupri or TPIP is successful in PAH trials or due to a potential takeover by a larger acquirer.
Key Retail Themes:
Potential success in PAH trials
Possibility of a takeover
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 1:11 AM ET
Data refreshes hourly during market hours. Next update: 2:11 AM
Data refreshes hourly during market hours. Next update: 2:11 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INSM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$91 | 56 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$266 | 55 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 49 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$132 | 52 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
22 analysts |
$107 | 33 SELL |
Advanced INSM Option Strategies
Professional options setups generated by AI based on today's INSM price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive INSM Research Pages
